A First-In-Human Study of LY3985297 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

June 7, 2024

Primary Completion Date

August 6, 2025

Study Completion Date

August 6, 2025

Conditions

Healthy

Interventions

DRUG

LY3985297

Administered either IV or SC.

DRUG

Placebo

Administered either IV or SC.

Trial Locations (2)

ICON, Salt Lake City

CenExel ACT, Anaheim

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT06395012 - A First-In-Human Study of LY3985297 in Healthy Participants | Biotech Hunter | Biotech Hunter